oxytocin

Oxytocin (Syntocinon) is a mammalian neuropituitary hormone, a pleiotropic hypothalamic peptide and ligand for the oxytocin receptor, which contributes to labor, lactation, and pro-social behavior. Oxytocin has the ability to stimulate mammary secretion of breast milk, promote contraction of uterine smooth muscle during labor, and facilitate mothering.

Oxytocin C-terminal tripeptide Acetate is the C-terminal tripeptide of Oxytocin.Oxytocin is a mammalian neuropituitary hormone, a ligand for the oxytocin receptor.

Oxytocin parallel dimer is a homo peptide dimer connected by a disulfide bridge.

Oxytocin antiparallel dimer is a disulfide-bridged homopeptide dimer.

Oxytocin free acid, also known as 9-Deamidooxytocin, is an analog of oxytocin where the glycinamide residue at position 9 has been substituted with a glycine residue. Oxytocin, a pleiotropic peptide hormone, has wide-ranging implications for general health, adaptation, development, reproduction, and social behavior.

[Leu3]-Oxytocin, an analogue of oxytocin, is a derivative wherein the leucine amino acid (Leu) replaces the amino acid at the 3rd position in the sequence.

[Glu4]-Oxytocin is a suitable derivative of oxytocin for conducting a thorough investigation, utilizing various methods, into the conformation of "oxytocin-like" molecules in aqueous solution.

[D-Asn5]-Oxytocin exhibits minimal specific oxytocic and vasodepressor effects. Comparative cumulative dose-response investigations reveal that [D-Asn5]-Oxytocin demonstrates a similar intrinsic activity to oxytocin in terms of oxytocic activity.

[Asp5]-Oxytocin is the first 5-position neurohypophyseal hormone analogue with significant biological activity.

(d(CH2)51,Tyr(Me)2, Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist used in neurological disease research [1].

Pro8-Oxytocin, a modified oxytocin (OXT) ligand, elicits more potent and efficacious responses at primate OXTR and induces stronger behavioral effects compared to the standard mammalian OXT ligand (Leu8-Oxytocin). It demonstrates lower efficacy than Vasopressin (AVP) at human AVPR1a, yet shows a higher efficacious response at marmoset AVPR1a [1].

Pro8-Oxytocin TFA, a modified oxytocin (OXT) ligand, exhibits greater potency and efficacy than the standard mammalian OXT ligand, Leu8-Oxytocin, at primate OXTR and elicits more pronounced behavioral effects. Compared to vasopressin (AVP), Pro8-Oxytocin TFA has a lower efficacious response at human AVPR1a, yet shows a higher efficacy at the marmoset AVPR1a [1].

(Val3,Pro8)-Oxytocin functions primarily as a Gq-dependent pathway agonist and exhibits secondary activity as a reduced efficacy agonist for β-arrestin recruitment and receptor-mediated endocytosis at the oxytocin receptor (OXTR) [1].

Oxytocin acetate (α-Hypophamine acetate) is a mammalian neurohypophysial hormone, a ligand of oxytocin receptor.

Retosiban is an effective and selective oxytocin antagonist (Ki: 0.65 nM).

Atosiban (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Epelsiban is a selective and orally bioavailable oxytocin receptor antagonist (pKi: 9.9 for human oxytocin receptor).

L-368,899 hydrochloride is an orally available and selective nonpeptide oxytocin receptor (OXTR) antagonist for the prevention of preterm labor.L-368,899 hydrochloride prevents oxytocin-induced anti-anomalous pain and anti-nausea, and may be useful for the study of depression.

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.

OT-R antagonist 2 is a nonpeptide, low molecular weight antagonist of OT-R (oxytocin receptor).

OT-R antagonist 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM). OT-R antagonist 1 is a new effective and selective nonpeptide low molecular weight OT-R antagonist.

L-371,257 is a competitive antagonist of oxytocin receptor with pA2 of 8.4 and Ki of 19 nM. L-371,257 shows a Ki of 3.7 nM for vasopressin receptor 1a.

Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth.